1. ALK

    Comments Leave a Comment

    1-15 of 122 1 2 3 4 5 6 7 8 »
    1. Mentioned In 122 Articles

    2. The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

      ...ts (FS-ALK) and a significant reduction in cell growth. We also demonstrate that ALK-I19 is a precursor of FS-ALK. ALK-I19 was detected in 14/37 (38%) tumors from patients with newly diagnosed NB. ALK-I19 expression corr...
      Read Full Article
      Mentions: ALK MYCN
    3. 1-15 of 122 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about ALK

    1. We have found that the effects of the HDAC8 inhibitor and the ALK inhibitor crizotinib add up, and that the two compounds together are significantly more effective than the two inhibitors alone.
      In Combination therapy in neuroblastoma: It`s all about the mix
    2. Exploitation of ALK as a therapeutic target in neuroblastoma
      In ANR 2010 ~ Days 1 & 2
    3. The updated data from the ongoing trial continue to demonstrate the anti-tumor activity of AP26113 in patients with crizotinib-resistant ALK rearranged NSCLC, as well as TKI-naïve ALK rearranged NSCLC.
      In ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer